Medical Injectables Program Update: Medications to be Added
Effective October 1, 2018, additional injectable medications will be included as part of our Medical Injectables Program (MIP) administered by Magellan Rx Management℠.
Beginning with services to be provided on and after October 1, 2018, Magellan Rx Management will conduct medical necessity and appropriateness reviews (MNARs) for the following additional injectable medications when these injectable medications are administered in a freestanding or hospital-based dialysis center, an outpatient facility, a patient’s home or a physician’s office.¹
These changes are based on the American Medical Association’s recommendations.
|Brand Name||Generic Name||HCPCS|
|VISCO-3||hyaluronan or derivative||J7321|
If you have questions, please contact your Network Specialist.
1 Medical necessity and appropriateness review is not required for injectable medications that are administered during an inpatient stay, or in an Emergency Room setting or Observation Room setting. For medical Injectable services rendered in the patient’s home, call 1-855-243-3321 for participating Horizon Care@Home health care professionals to obtain pre-service determination.
2 Horizon BCBSNJ is currently developing a medical policy for ONCASPAR (Pegaspargase). This drug will be added to the MIP on November 1, 2018, to coincide with the implementation date of this new policy. Unless Horizon BCBSNJ provides notice of the cancellation or postponement of this new policy, ONCASPAR will be included as part of our MIP beginning November 1, 2018.
Magellan Rx ManagementSM is a service mark of Magellan Health, Inc.